About 2-phosphoxylose phosphatase 1
2-phosphoxylose phosphatase 1 (PXYLP1) is a protein
from Homo sapiens identified by UniProt accession
Q8TE99, 480 residues long.
MolForge cross-references it against 0 known binders and
92 disease associations.
Target properties
| Protein name | 2-phosphoxylose phosphatase 1 |
| UniProt accession | Q8TE99 |
| Gene | PXYLP1 |
| Organism | Homo sapiens |
| Length | 480 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (92)
Diseases linked to this target (Open Targets).
- neutrophil count · score 0.45
- leukocyte count · score 0.44
- myeloid white cell count · score 0.40
- lymphocyte count · score 0.33
- neutrophil percentage of leukocytes · score 0.28
- granulocyte count · score 0.26
- sum of neutrophil and eosinophil counts · score 0.26
- sum of basophil and neutrophil counts · score 0.25
- monocyte percentage of leukocytes · score 0.24
- body height · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8TE99-F1 | alphafold | PREDICTED | 89.30 | — |
Amino-acid sequence (480 residues)
MLFRNRFLLL LALAALLAFV SLSLQFFHLI PVSTPKNGMS SKSRKRIMPD PVTEPPVTDP VYEALLYCNI PSVAERSMEG HAPHHFKLVS VHVFIRHGDR YPLYVIPKTK RPEIDCTLVA NRKPYHPKLE AFISHMSKGS GASFESPLNS LPLYPNHPLC EMGELTQTGV VQHLQNGQLL RDIYLKKHKL LPNDWSADQL YLETTGKSRT LQSGLALLYG FLPDFDWKKI YFRHQPSALF CSGSCYCPVR NQYLEKEQRR QYLLRLKNSQ LEKTYGEMAK IVDVPTKQLR AANPIDSMLC HFCHNVSFPC TRNGCVDMEH FKVIKTHQIE DERERREKKL YFGYSLLGAH PILNQTIGRM QRATEGRKEE LFALYSAHDV TLSPVLSALG LSEARFPRFA ARLIFELWQD REKPSEHSVR ILYNGVDVTF HTSFCQDHHK RSPKPMCPLE NLVRFVKRDM FVALGGSGTN YYDACHREGF
Explore 2-phosphoxylose phosphatase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets